Halozyme Therapeutics HALO Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's operating lease ROU assets?
- Halozyme Therapeutics (HALO) reported operating lease ROU assets of $35.3M in Q1 2026.
- How has Halozyme Therapeutics's operating lease ROU assets changed year-over-year?
- Halozyme Therapeutics's operating lease ROU assets increased by 8.3% year-over-year, from $32.59M to $35.3M.
- What is the long-term trend for Halozyme Therapeutics's operating lease ROU assets?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's operating lease ROU assets has grown at a 62.8% compound annual growth rate (CAGR), from $3.3M to $37.7M.
- What does operating lease ROU assets mean?
- This asset represents the company's right to use a leased item, such as office space or data center facilities, over the lease term. It is recognized under modern accounting standards to reflect the financial commitment of long-term operating leases. It provides visibility into the company's fixed operational footprint.